Eubel Brady & Suttman Asset Management’s Merck MRK Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04M	Buy	8,638 +254	+3%	+$29.3K	0.12%	58
2025 Q4	$883K	Sell	8,384 -8	-0.1%	-$751	0.1%	63
2025 Q3	$704K	Buy	8,392 +2,526	+43%	+$208K	0.08%	66
2025 Q2	$464K	Sell	5,866 -200	-3%	-$15.9K	0.06%	70
2025 Q1	$544K	Buy	6,066 +768	+14%	+$71.7K	0.07%	65
2024 Q4	$527K	Hold	5,298	–	–	0.07%	63
2024 Q3	$602K	Sell	5,298 -254	-5%	-$30.2K	0.08%	62
2024 Q2	$687K	Buy	5,552 +789	+17%	+$102K	0.1%	61
2024 Q1	$628K	Buy	4,763 +5	+0.1%	+$616	0.08%	63
2023 Q4	$519K	Buy	4,758 +106	+2%	+$11K	0.07%	68
2023 Q3	$479K	Buy	4,652 +105	+2%	+$11.3K	0.07%	70
2023 Q2	$525K	Buy	4,547 +4	+0.1%	+$454	0.07%	67
2023 Q1	$483K	Buy	4,543 +30	+0.7%	+$3.24K	0.07%	70
2022 Q4	$501K	Buy	4,513 +6	+0.1%	+$613	0.08%	69
2022 Q3	$388K	Buy	4,507 +5	+0.1%	+$446	0.07%	71
2022 Q2	$410K	Buy	4,502 +6	+0.1%	+$532	0.08%	60
2022 Q1	$369K	Buy	4,496 +6	+0.1%	+$473	0.07%	60
2021 Q4	$344K	Buy	4,490 +10	+0.2%	+$796	0.07%	65
2021 Q3	$336K	Sell	4,480 -292	-6%	-$22.2K	0.07%	57
2021 Q2	$368K	Sell	4,772 -5,230	-52%	-$389K	0.03%	145
2021 Q1	$736K	Buy	10,002 +6,218	+164%	+$459K	0.08%	62
2020 Q4	$295K	Hold	3,784	–	–	0.07%	64
2020 Q3	$299K	Buy	3,784 +1	+0%	+$78	0.08%	60
2020 Q2	$279K	Buy	3,783 +108	+3%	+$8.13K	0.07%	63
2020 Q1	$270K	Buy	3,675 +4	+0.1%	+$314	0.08%	61
2019 Q4	$319K	Buy	3,671 +3	+0.1%	+$246	0.09%	60
2019 Q3	$295K	Buy	3,668 +3	+0.1%	+$240	0.08%	63
2019 Q2	$293K	Buy	3,665 +4	+0.1%	+$306	0.08%	62
2019 Q1	$291K	Buy	3,661 +3	+0.1%	+$224	0.09%	58
2018 Q4	$267K	Buy	3,658 +4	+0.1%	+$282	0.09%	60
2018 Q3	$247K	Buy	3,654 +4	+0.1%	+$255	0.07%	66
2018 Q2	$211K	Sell	3,650 -363	-9%	-$20.5K	0.07%	68
2018 Q1	$209K	Buy	4,013 +4	+0.1%	+$216	0.07%	63
2017 Q4	$215K	Buy	4,009 +5	+0.1%	+$277	0.06%	70
2017 Q3	$245K	Sell	4,004 -83	-2%	-$5.03K	0.08%	69
2017 Q2	$250K	Buy	4,087 +90	+2%	+$5.48K	0.08%	68
2017 Q1	$242K	Sell	3,997 -69	-2%	-$4.19K	0.07%	68
2016 Q4	$228K	Buy	4,066 +4	+0.1%	+$234	0.07%	71
2016 Q3	$242K	Sell	4,062 -14	-0.3%	-$819	0.08%	71
2016 Q2	$224K	Buy	4,076 +5	+0.1%	+$266	0.07%	68
2016 Q1	$206K	Buy	+4,071	New	+$199K	0.07%	70
2015 Q3	–	Sell	-3,745	Closed	-$203K	–	82
2015 Q2	$203K	Buy	3,745 +5	+0.1%	+$280	0.07%	73
2015 Q1	$205K	Buy	+3,740	New	+$212K	0.06%	74

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's MRK Position: Q1 2026 in Review

Eubel Brady & Suttman Asset Management increased its Merck (MRK) stake by 3% in Q1 2026, buying an estimated $29.3K and bringing the position to 8,638 shares worth $1.04M. The position accounts for 0.12% of the portfolio, ranked #58.

Eubel Brady & Suttman Asset Management first reported a position in MRK in Q1 2015 and has held it in 43 quarters since. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

Eubel Brady & Suttman Asset Management held 8,638 shares of Merck worth $1.04M as of Q1 2026.
Eubel Brady & Suttman Asset Management bought 254 Merck shares in Q1 2026, an estimated $29.3K.
Merck made up 0.12% of Eubel Brady & Suttman Asset Management's portfolio in Q1 2026, its #58 holding.
Eubel Brady & Suttman Asset Management first reported a position in Merck in Q1 2015 and has held it in 43 quarters since.
3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q1 2026, filed 11 May 2026.